BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 25038756)

  • 1. Regulation and Role of EZH2 in Cancer.
    Yamaguchi H; Hung MC
    Cancer Res Treat; 2014 Jul; 46(3):209-22. PubMed ID: 25038756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The noncanonical role of EZH2 in cancer.
    Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
    Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.
    Lu H; Li G; Zhou C; Jin W; Qian X; Wang Z; Pan H; Jin H; Wang X
    Am J Cancer Res; 2016; 6(12):2737-2754. PubMed ID: 28042497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Going beyond Polycomb: EZH2 functions in prostate cancer.
    Park SH; Fong KW; Mong E; Martin MC; Schiltz GE; Yu J
    Oncogene; 2021 Sep; 40(39):5788-5798. PubMed ID: 34349243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
    Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
    Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Roles of LncRNAs in the EZH2-regulated Oncogenic Network.
    Hao A; Wang Y; Stovall DB; Wang Y; Sui G
    Int J Biol Sci; 2021; 17(13):3268-3280. PubMed ID: 34512145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.
    Gan L; Yang Y; Li Q; Feng Y; Liu T; Guo W
    Biomark Res; 2018; 6():10. PubMed ID: 29556394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-canonical functions of EZH2 in cancer.
    Zimmerman SM; Lin PN; Souroullas GP
    Front Oncol; 2023; 13():1233953. PubMed ID: 37664059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.
    Alzrigat M; Jernberg-Wiklund H; Licht JD
    Epigenomes; 2018 Sep; 2(3):. PubMed ID: 30761216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2-mediated development of therapeutic resistance in cancer.
    Kaur P; Shankar E; Gupta S
    Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.
    Marchesi I; Bagella L
    World J Clin Oncol; 2016 Apr; 7(2):135-48. PubMed ID: 27081636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of T Cell Differentiation and Function by EZH2.
    Karantanos T; Chistofides A; Barhdan K; Li L; Boussiotis VA
    Front Immunol; 2016; 7():172. PubMed ID: 27199994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2: novel therapeutic target for human cancer.
    Li LY
    Biomedicine (Taipei); 2014; 4(1):1. PubMed ID: 25520914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
    Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
    Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
    Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
    Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No Easy Way Out for EZH2: Its Pleiotropic, Noncanonical Effects on Gene Regulation and Cellular Function.
    Wang J; Wang GG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33327550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse involvement of EZH2 in cancer epigenetics.
    Völkel P; Dupret B; Le Bourhis X; Angrand PO
    Am J Transl Res; 2015; 7(2):175-93. PubMed ID: 25901190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
    Au SL; Wong CC; Lee JM; Wong CM; Ng IO
    PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.